(19)
(11) EP 2 262 777 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
04.05.2016 Bulletin 2016/18

(45) Mention of the grant of the patent:
24.02.2016 Bulletin 2016/08

(21) Application number: 09718101.0

(22) Date of filing: 06.03.2009
(51) International Patent Classification (IPC): 
C07D 231/54(2006.01)
A61K 31/416(2006.01)
A61P 3/10(2006.01)
A61P 13/00(2006.01)
 C07D 401/12(2006.01)
A61K 31/435(2006.01)
A61P 9/00(2006.01)
(86) International application number:
PCT/EP2009/052660
(87) International publication number:
WO 2009/109654 (11.09.2009 Gazette 2009/37)

(54)

1-BENZYL-3-HYDROXYMETHYLINDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF MCP-1 AND CX3CR1

1-BENZYL-3-HYDROXYMETHYLINDAZOLDERIVATE UND IHRE VERWENDUNG BEI DER BEHANDLUNG VON AUF DER EXPRESSION VON MCP-1 UND CX3CR1 BASIERTEN ERKRANKUNGEN

DÉRIVÉS DE 1-BENZYL-3-HYDROXYMETHYLINDAZOLE ET UTILISATION ASSOCIÉE DANS LE TRAITEMENT DES MALADIES BASÉ SUR L'EXPRESSION DE MCP-1 ET CX3CR1

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR

(30) Priority: 07.03.2008 EP 08425141

(43) Date of publication of application:
22.12.2010 Bulletin 2010/51

(73) Proprietor: Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
00181 Roma (IT)

(72) Inventors:
  • GUGLIELMOTTI, Angelo
    I-00149 Roma (IT)
  • FURLOTTI, Guido
    I-00151 Roma (IT)
  • MANGANO, Giorgina
    I-00139 Roma (IT)
  • CAZZOLLA, Nicola
    I-00041 Albano Laziale (roma) (IT)

(74) Representative: Allaix, Roberto 
Marchi & Partners S.r.l. Via Vittor Pisani, 13
20124 Milano
20124 Milano (IT)


(56) References cited: : 
WO-A-99/04770
US-A1- 2007 043 057
 US-A1- 2006 047 126
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).